Litcius/Paper detail

Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial

Bradley J. Monk, Krishnansu S. Tewari, Coraline Dubot, M. Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yañez, Mahmut Gümüş, Mivael Olivera Hurtado de Mendoza, Vanessa Samouëlian, Vincent Castonguay, Arkhipov Alexander, Cumhur Tekin, Kan Li, Allison Martin Nguyen, Matthew Monberg, Nicoletta Colombo, Domenica Lorusso

2023The Lancet Oncology70 citationsDOIOpen Access PDF

Topics & Concepts

MedicineBevacizumabPembrolizumabCarboplatinChemotherapyPlaceboClinical endpointInternal medicineCervical cancerOncologyCancerSurgeryClinical trialCisplatinImmunotherapyPathologyAlternative medicineEndometrial and Cervical Cancer TreatmentsCancer Immunotherapy and BiomarkersColorectal and Anal Carcinomas
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial | Litcius